We aimed to identify novel HBV T-cell epitopes by examining the relationship between HBV sequence variation and the human leukocyte antigen (HLA) type in a large prospective clinic-based cohort of Asian patients with chronic HBV infection recruited in Australia and China (n ‫؍‬ 119). High-resolution 4-digit HLA class I and II typing and full-length HBV sequencing were undertaken for treatment-naïve individuals (52% with genotype B, 48% with genotype C, 63% HBV e antigen [HBeAg] positive). Statistically significant associations between HLA types and HBV sequence variation were identified (n ‫؍‬ 49) at 41 sites in the HBV genome. Using prediction programs, we determined scores for binding between peptides containing these polymorphisms and associated HLA types. Among the regions that could be tested, HLA binding was predicted for 14/18 (78%). We identified several HLAassociated polymorphisms involving likely known anchor residues that resulted in altered predicted binding scores. Some HLAassociated polymorphisms fell within known T-cell epitopes with matching HLA restriction. Enhanced viral adaptation (defined as the presence of the relevant HLA and the escaped amino acid) was independently associated with HBeAg-negative disease (P ‫؍‬ 0.003). Thus, HBV appears to be under immune pressure in chronic HBV infection, particularly in HBeAg-negative disease. G lobally, infection with hepatitis B virus (HBV) is common, and despite an effective vaccine, the number of persons with chronic HBV infection is increasing (9). Broad and effective HBVspecific T-cell responses are required to clear acute HBV infection (7, 37), but circulating HBV-specific T cells are rarely detected in chronic HBV infection (7, 8) . It is therefore unclear whether the adaptive immune response plays a role in controlling viral replication in chronic HBV infection and whether changes or adaptations in HBV are selected due to immune pressure.
G
lobally, infection with hepatitis B virus (HBV) is common, and despite an effective vaccine, the number of persons with chronic HBV infection is increasing (9) . Broad and effective HBVspecific T-cell responses are required to clear acute HBV infection (7, 37) , but circulating HBV-specific T cells are rarely detected in chronic HBV infection (7, 8) . It is therefore unclear whether the adaptive immune response plays a role in controlling viral replication in chronic HBV infection and whether changes or adaptations in HBV are selected due to immune pressure.
In individuals with chronic HBV infection, as many as 10 11 virus particles are produced per day (21, 30) . HBV reverse transcriptase lacks proofreading activity, resulting in mutation rates estimated at 1.5 ϫ 10 Ϫ5 to 5 ϫ 10 Ϫ5 nucleotide substitutions per site per year in HBV e antigen (HBeAg)-positive individuals (32) .
Due to overlapping open reading frames (ORF), HBV genome evolution is constrained to maintain essential protein functions required for replication (28) . There is some evidence that changes in HBV sequences can be selected due to host immune pressure (2, 5, 23) and that the HBV mutation rate is even higher in HBeAgnegative individuals (15, 33) , possibly due to increased immune pressure prior to HBeAg loss (4, 10, 15) or due to higher levels of virus replication in the absence of HBeAg, given the known inhibitory effect of HBeAg on HBV replication at the level of nucleocapsid maturation or stability (13) . This suggests that the host immune response plays an important role in HBV evolution.
The human leukocyte antigen (HLA) molecules determine how foreign peptides are presented to T cells. Population-based genetic approaches have identified statistically significant associations between specific HLA types and polymorphisms (adaptations) in human immunodeficiency virus (HIV) and hepatitis C virus (HCV) (12, 29, 31, 45) . Many HLA-associated viral polymorphisms in HIV-and HCV-infected patients were within known T-cell epitopes, consistent with immune pressure (12, 29) . These sites of adaptation were subsequently used to identify novel T-cell epitopes for both HIV and HCV (16, 20, 36) . In this study, we examined the relationship between HBV polymorphisms and specific HLA types in an Asian population in order to find evidence of viral evolution of HBV at a population level and to determine whether viral adaptation was associated with clinical outcomes. Additionally, we aimed to use these data to identify putative novel HBV epitopes in an Asian population.
MATERIALS AND METHODS
Subjects. HBV-infected individuals of ethnic Chinese origin were recruited from the Queen Mary Hospital in Hong Kong, China (n ϭ 141), and from St. Vincent's Hospital (n ϭ 51), The Alfred (n ϭ 11), and Box Hill Hospital (n ϭ 18) in Melbourne, Australia. Chronic HBV infection was defined by the presence of detectable HBV surface antigen (HBsAg) on two occasions more than 6 months apart, and all individuals were naïve to antiviral therapy. All individuals were HIV and HCV antibody negative. Clinical, biochemical, immunological, and virological details were obtained from prospectively maintained clinic databases and/or retrospective case record review. The study was undertaken with written informed consent from each individual, and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, and was approved by the local ethics committees. HBV DNA quantification. In Melbourne, HBV DNA was quantified with the HBV Digene Hybrid Capture II microplate assay (Digene Diagnostics, Beltsville, MD) or the Versant HBV DNA 3.0 assay (Siemens Healthcare Diagnostics, Tarrytown, NY), in accordance with the manufacturer's instructions. The lower limit of detection (LLD) of the Digene Hybrid Capture II microplate assay was approximately 24,912 IU/ml, and that of the Versant HBV DNA 3.0 assay was 357 IU/ml. For samples from Hong Kong, HBV DNA was quantified using an in-house TaqMan assay amplifying the core region, with an LLD of 77 IU/ml. Therefore, an LLD of 357 IU/ml was used for all individuals. Alanine aminotransferase (ALT) levels were considered increased if they were Ն40 U/liter for the Box Hill Hospital and Alfred cohorts, Ն35 U/liter for the St. Vincent's cohort, or Ն80 U/liter for the Hong Kong cohort.
PCR and sequencing. HBV DNA was extracted from 200 l of serum using the QIAamp DNA Mini kit (Qiagen, Dusseldorf, Germany) according to the manufacturer's instructions. The purified DNA was eluted in a final volume of 50 l. HBV DNA was amplified by PCR using the PicoMaxx high-fidelity PCR system (Stratagene, La Jolla, CA) and the method adapted from Günther et al. (14) . The sequencing assay has an LLD of roughly 2,000 IU/ml, because a high-fidelity enzyme is required to amplify a relatively large piece of DNA. Samples with viral loads greater than 2,000 IU/ml generally required only one round of PCR. A second round of PCR was performed for samples with low viral loads (between 357 and 2,000 IU/ml) by amplifying two overlapping DNA fragments with primers P1 and 1798* (nucleotides [nt] 1799 to 1820) (3=-CCAACTGCATGGCCTG AGGATG-5=) and primers JM* (nt 1676 to 1696) (3=-TTGGGGTGGAG CCCTCAGGCT-5=) and P2, using 2 l of the first-round product as the template with 25 cycles. Consensus sequences were determined for each genotype and HBV protein, and the amino acids (aa) for each protein and genotype were compared in order to determine percentages of difference per genotype and protein. Polymorphism was defined as the overall percentage of nonconsensus amino acids at a particular residue.
Cloning. Cloning was undertaken for mixed populations (those for which the secondary peak was Ͼ20% of the main peak) in 14 patients (1 with genotype B and 13 with genotype C). Cloning was performed using the Topo XL TA cloning kit (Invitrogen, Mt. Waverley, Australia), and on average, 5 clones were selected and 2 to 4 clones were sequenced for each patient. The sequences of the individual clones for each subject were then used in the analysis.
HLA typing. High-resolution HLA class I (HLA-A, -B, and -C) and II (HLA-DRB1) typing was performed as described previously (48) . Allele assignments (Table 1) were made using the Assign program (Conexio Genomics, Fremantle, Australia). This program utilizes the database of HLA allele sequences on the IMGT/HLA website (http://www.ebi.ac.uk /imgt/hla/). Generally, ambiguities were resolved following sequencing with allele-specific subtyping primers. However, for a few individuals, identity at exons 2 and 3 was consistent with the presence of rare alternative and null alleles, and in these rare cases, the allele assignment was based on the most commonly expressed allele and haplotype combination in the relevant population (http://www.allelefrequencies.net/). Phylogenetic analysis. Deduced HBV aa sequences from the different proteins were aligned using ClustalX. Phylogenetic analysis of the HBV polymerase (Pol) protein was carried out using the neighbor-joining method based on the p-distance model with pairwise deletion and the modified Nei-Gojobori method (49) . The mean genetic distances (mean numbers of differences/sequence length) between and within genotype Band genotype C-infected individuals were determined using the same alignments. All analyses were performed using MEGA, version 3.1 (44) .
Statistical methods. (i) Association between specific HLA alleles and viral polymorphism. Statistical analysis of specific associations between HLA alleles and viral polymorphism, including assessment of any impact of founder effects, followed the methods described by Rauch et al. (36) . Analyses were carried out in TIBCO Spotfire Sϩ (Tibco Software, Inc.). Because this study was the first to examine HBV viral adaptation using this approach, a nonconservative cutoff was used to identify viral adaptations, based on a Fisher P value of Ͻ0.05 and a cluster-corrected MantelHaenszel P value of Ͻ0.1. While false discovery rates and associated q-values as described by Rauch et al. (36) can be obtained for these data, the relatively small sample sizes precluded sensible estimation, and they are not reported here. Odds ratios (OR) for association were compared across genotypes via log-linear models.
(ii) Correlation between host viral adaptation and clinical parameters. For all HBV proteins, an individual's "adaptation score" was defined as the number of residues for which the individual had at least one of the relevant HLAs with a defined association and the escaped aa was present. Relationships between the adaptation score and the clinical parameters ALT level, HBeAg status, and HBV DNA level were assessed via analyses appropriate to the nature of the data; the continuous variable ALT level Peptide-HLA ligation. Putative novel HLA class I and II epitopes were screened using the BIMAS (34), SYFPEITHI (35) , and Immune Epitope (47) databases of predictive algorithms of peptide-HLA interaction (when the relevant HLA type was available in the databases). Cutoffs for "good" epitopes were set at scores of 18 and 50 for SYFPEITHI and BIMAS, respectively, as described previously (36) . These algorithms estimate the strength of ligation between a specific aa sequence and a defined HLA type. These algorithms have been validated previously by comparing the predictive binding of a particular aa, based on its side chain structure, with its actual binding (34) . For each open reading frame, screening was undertaken by testing HLA-sequence binding using the aa sequences surrounding a site associated with a specific HLA allele (Ϯ 13 aa for HLA class I and Ϯ 17 aa for HLA class II).
RESULTS
Study recruitment and participants. Patient recruitment and demographic characteristics are described in Fig. 1 and Table 2 .
HBV polymorphism rate. The polymorphism rate at each residue was calculated as the proportion of patients infected with HBV who had a nonconsensus residue at that site. The HBV polymorphism rate differed at each residue across the genome, ranging from 0% to 49% for genotype B and 0% to 53% for genotype C (Fig. 2) . We then compared the degree of aa variation between the consensus genotype B and C sequences for each HBV protein and found differences at 91/843 (10.8%) sites for Pol, 49/400 (12.2%) sites for pre-S, 17/154 (11%) sites for X protein, and 0/211 (0%) sites for core. The difference for core between genotypes B and C was lower than those for the other proteins (P Ͻ 0.00001).
The intergenotype mean genetic distance (0.09) was greater than the intragenotype mean genetic distance (0.03). The synonymous and nonsynonymous genetic distances within each genotype across the proteins were similar, reflecting the maintenance of the basic structure and function of the proteins within both genotypes ( Table  3) . As with HCV (36), these genotype differences are likely to have an impact on potential sites of escape from HLA-restricted immune pressure across the genome. Therefore, all subsequent analyses were performed separately for genotypes B and C.
Phylogenetic analysis. We then analyzed all HBV sequences in order to determine the relatedness of the sequences to each other. Phylogenetic analysis revealed clustering within the main genotype, with strong bootstrap support (Fig. 3) . There was further clustering of sequences within each specific genotype, mainly representing subgenotypes. The methods used accounted for the clustering within the tree, and therefore, we concluded that any HLA-associated viral polymorphisms were not likely to be due to aa changes specific to a subcluster. The lack of clustering (outside the genotype and subgenotypes) confirmed that sequences from subjects recruited from each site could be combined for HLA/polymorphism analysis but that genotype B and C sequences should be analyzed separately (as discussed above). HLA-associated viral polymorphisms representing putative viral adaptations. We identified 49 statistically significant asso- (Table 4) . Four of the associations had an OR of Ͻ1, indicating that the consensus sequence had the adapted (or "escaped") aa (12, 29) , and in one case, two different residues occurred with equal frequency in the consensus sequence. There was clustering of associations (involving different HLA types and genotypes) at certain amino acids. For example, the polymorphism at Pol aa 470 was associated with HLA-A*0201 (genotype B) and HLA-A*2402 (genotype C) ( Table 4) . Two or more HLA types were associated with polymorphisms at Pol aa 104 (genotype B) and 602 (genotype B), core aa 89 (genotype B) and 180 (genotype B), and X protein aa 131 (genotype C), 47 (genotype B), and 143 (genotype B).
HBV genotype and HLA-associated viral polymorphisms. There was no overlap in specific 2-digit or 4-digit HLAassociated viral polymorphisms, and overall, there was no evidence of a difference in HLA distribution between genotypes B and C (P Ͼ 0.1). However, some HLA types were overrepresented in genotype B (including HLA-A*0206 [P ϭ 0.038], HLA-B*1502 [P ϭ 0.034], and HLA-DRB1*1202 [P ϭ 0.04]), and others were underrepresented in genotype B (HLA-A*0203 [P ϭ 0.02]). We then examined the frequency of variation for each of the 49 HLA (4-digit)-associated viral polymorphisms (corresponding to 41 sites) for the alternate genotype. Ten of the 49 (20%) HLA associations could not be compared between the genotypes, since fewer than 5 patients infected with the alternate genotype carried the specific HLA type. Of the remaining 39 residues that could be compared, 12 (31%) were completely conserved in the alternate genotype, even though the specific HLA type was present in patients with that genotype. Furthermore, 21 of the 41 (51%) sites differed in the consensus sequence between the genotypes. The differences in the polymorphism and escape pattern between genotypes are highlighted in Fig. 4 .
HLA-associated viral polymorphisms within known HBV T-cell epitopes.
We then looked to determine if the HLAassociated viral polymorphisms we identified were located in known HBV epitopes. We examined all published epitopes from all HBV genotypes (summarized and reviewed in reference 8). When we examined prior reports that also used 4-digit HLA typing, we identified two HLA-associated viral polymorphisms within previously published HBV epitopes with the same HLA restriction. The HLA-A*0201-associated polymorphism at aa 195 within the genotype B envelope protein occurred within the known HLA-A*0201-restricted epitopes pre-S1 aa 188 to 196 (S aa 14 to 22) (7, 42) and pre-S1 aa 194 to 202 (S aa 20 to 28) (22) (Fig.  4 and 5 ; Table 5 ) (position 195; OR, 15; confidence interval [CI], 1.3 to 264; P ϭ 0.01). The pre-S1 aa 194-to-202 (S aa 20-to-28) epitope has been demonstrated to elicit specific cytotoxic T-lymphocyte responses in HLA-A2 Chinese patients with a pre-S1 aa 194-to-202 (S aa 20-to-28) sequence identical to that of our patients (22) . Pre-S1 aa 195 involved the primary anchor position within the HLA-A*0201 T-cell epitope, where mutation could potentially abrogate HLA binding. The additional HLA-A*0201-associated polymorphism at aa 384 within the genotype C envelope protein occurred within the known HLA-A*0201-restricted epitopes pre-S1 aa 381 to 390 (S aa 207 to 216) (38) and pre-S1 aa 382 to 390 (S aa 208 to 216) (18) (Fig. 5 ; Table 5 ) (position 384; OR, 5; CI, 0.8 to 35; P ϭ 0.04). The pre-S1 aa 382-to-390 (S aa 208-to-216) epitopes (18) had been identified in genotype C-infected individuals.
When we examined the list of HLA associations based on 2-digit typing (data not shown), we found a further three possible HLA allele-specific viral polymorphisms that flanked known CD8 T-cell epitopes, including HLA A*11-associated polymorphisms at core aa 116 (OR, 7.3; CI, 1.1 to 479; P ϭ 0.01) and aa 126 (OR, 5.3; CI, 0.8 to 356; P ϭ 0.096) and an HLA A*02-associated polymorphism at X protein aa 143 (OR, 0.05; CI, 0 to 0.6; P ϭ 0.006). The association between HLA A*02 and X protein aa 143 favored conservation of the wild-type sequence. These associations did not reach statistical significance in the 4-digit analysis, most likely because the HLA-A*11 and HLA-A*02 alleles have more than one main subtype, which were analyzed separately in our 4-digit analysis.
These data therefore support the validity of our populationbased approach to identifying novel T-cell epitopes.
HLA-associated viral polymorphisms within putative novel HBV T-cell epitopes. In order to determine whether HLAassociated viral polymorphisms not located within known epitopes were of potential biological significance, we used the Web-based epitope prediction programs (SYFPEITHI, BIMAS, and the Immune Epitope database) to determine predicted binding of the viral sequence and associated HLA type. Predicted putative epitopes were identified within all HBV proteins (Table 5 ). In addition, we identified putative aa escape polymorphisms that were associated with lower predicted HLA binding in several of these epitopes, many located at likely anchor residues (Table 5 ).
Although not yet tested in functional assays using T cells from patients with chronic HBV, these data provide strong supportive evidence that many of the HLA-associated polymorphisms newly identified in this study are likely to be within HBV T-cell epitopes.
Host viral adaptation and clinical parameters. We then asked whether the degree of adaptation of HBV was associated with any clinical parameters at a population level. We defined adaptation as the number of residues for which the individual had at least one of the relevant HLAs with a defined association and the putative escaped aa was present. Among patients infected with genotype B, we found that adaptation was significantly lower in HBeAgpositive than in HBeAg-negative patients (P ϭ 0.0155) (Fig. 6) . This difference remained significant after adjustment for gender, recruitment site, ALT level, and HBV DNA level (P Ͻ 0.001).
Among patients infected with genotype C, we also observed lower adaptation in HBeAg-positive than in HBeAg-negative patients, but this difference did not reach significance in an unadjusted analysis (P ϭ 0.15) (Fig. 6 ). However, after adjustment for gender, recruitment site, and HBV DNA level, lower adaptation was significantly associ- ated with HBeAg-positive status, as we found for genotype B (P Ͻ 0.02). Combined analysis of genotypes B and C indicated no difference between the genotypes for an association between HBeAg and adaptation (P Ͼ 0.2). In the combined analysis, HBeAg-positive status and adaptation were again strongly associated (P ϭ 0.003).
There was no evidence that adaptation was associated with lower HBV DNA levels in genotype B (P ϭ 0.45) or genotype C (P ϭ 0.5) (Fig. 6 ). There was no significant relationship between adaptation and ALT levels for either genotype B or genotype C (P, 0.72 and 0.17, respectively) (Fig. 6) . 
DISCUSSION
We performed full-length HBV sequencing and high-resolution HLA typing for a large cohort of Asian individuals chronically infected with HBV genotype B or genotype C and identified 49 statistically significant associations between viral polymorphisms and HLA type, including associations within previously defined HLA-matched T-cell epitopes. Novel epitopes involving all HBV proteins and potential escape mutations were also identified. Of these putative epitopes, we were able to predict HLA binding for 14/18 (78%) associations, and we identified polymorphisms associated with reduced binding. Polymorphisms occurred in likely anchor residues, consistent with other escape mutations (6, 39) . Finally, we found a significant association between viral adaptation within a host and the absence of HBeAg. Taken together, these data demonstrate that HBV is under significant immune pressure at a population level and that this is most prominent in HBeAg-negative individuals. This is the first large population-based study aimed at identifying novel HBV epitopes in a cohort of Asian individuals, who have HLA types vastly different from those of Caucasians. The majority of known HBV HLA class I-restricted epitopes have been identified in individuals with HLA-A2. However, 75% of individuals with chronic HBV infection reside in Asia (19, 24) , where HLA-A24 is the most common HLA class I allele (43) . Furthermore, HLA-A11 is present in 52% of Chinese individuals and 14% of Caucasians, and HLA-B40 is present in 32% of Chinese individuals and 15% of Caucasians (25) (results consistent with those obtained in this study [ Table 1 ]). Additionally, there are substantial differences in allele subtypes. More than 95% of Caucasians with HLA-A2 have HLA-A0201, whereas subtypes HLA-A*0203, HLA-A*0206, and HLA-A*0207 are present in 23%, 10%, and 45% of HLA-A2 individuals of Chinese origin, respectively (17) .
Given the degree of constraint on HBV viral evolution, largely as a result of overlapping ORF, we found a surprisingly high degree of viral sequence variability, and this differed for genotype B and genotype C. The mean intragenotype genetic distance for genotypes B and C was 0.03, similar to the intragenotype value of 0.05 previously reported for nonstructural protein 3 of HCV genotype 1 sequences (12, 36) . Nonstructural protein 3 is the most conserved of the nonstructural proteins in HCV. The intergenotype genetic distance for HCV genotypes 1 and 3 was much higher than that observed for HBV (0.20 for HCV versus 0.09 for HBV), reflecting greater diversity overall for HCV than for HBV. Furthermore, in support of the hypothesis that viral escape is driven by host immune pressure and is restricted by viral (genotype) characteristics, we found substantial differences in the consensus sequences for HBV genotypes B and C that may abrogate HLA binding to critical anchor residues within viral epitopes (Fig. 4) .
We identified HLA-associated viral polymorphisms that were located within previously described epitopes, providing support for this population-based methodology. In a recent study of New Zealand Tongans with chronic hepatitis B (CHB) with known specific HLA types (mainly HLA-B*4001 and HLA-B*5602 in patients with genotype C and D infections), 13 sites in the HBV genome under significant positive selection pressure were identified, and 5 of these sites were associated with a specific HLA type (1) . One of these significant associations was between HLA-B*4001 and position 106 (equivalent to position 77 in reference 1), the same association found in our cohort, but by use of a different approach, identifying adaptation rather than selection.
After adjusting for gender, recruitment site, and HBV DNA level, we found significantly lower adaptation in HBeAgpositive individuals for both genotypes B and C. These findings are consistent with those of another study comparing HBV sequences in individuals over a 20-to 35-year period, where HBeAg-positive asymptomatic carriers with very high levels of HBV DNA had highly conserved nucleotide sequences (33) . In contrast, mutations were seen in HBeAg-negative carriers (mean, 20 mutations) and were distributed over all regions of the viral genome, occurring more frequently in putative CD8 T-cell epitopes (33) . One potential interpretation of these findings and ours is that in the absence of HBeAg and its "suppressive" effect on the immune response, the HBV sequence evolves more rapidly (26, 27, 46) . HBeAg leads to reduction of toll-like receptor-2 expression on monocytes (40) and inefficient release of the inflammatory cytokine tumor necrosis factor alpha. This promotes an imbalance of T helper 1 (Th-1)/Th-2 responses, the production of anti-inflammatory cytokines, such as interleukin 4 (IL-4) and IL-10, and the suppression of HBeAg/HBcAg-specific CD8 ϩ T-cell responses (11) . This "suppressive" cytokine profile is reversed following seroconversion from HBeAg to HBV e antibody (HBeAb), leading to increases in IL-12 and gamma interferon levels (a Th-1 cytokine profile), which may enhance CD8 ϩ T-cell function (41) . Increased activity of the innate and adaptive immune system during the HBeAg-negative phase may therefore allow for increased immune pressure, leading to an accumulation of mutations due to immune escape (4, 10, 15) . However, this interpretation can be directly addressed only by examining epitopespecific responses and potential specific escape mutations over time prior to and following HBeAg seroconversion, which we were unable to do in this study.
We were surprised not to identify an association between adaptation and other clinical parameters, such as the HBV DNA load. Given that HBV has a small and compact genome with multiple overlapping reading frames, any changes in one protein will lead to changes in another protein (that shares the overlapping reading frame). These secondary changes could potentially alter fitness and therefore may not necessarily result in a change in HBV DNA load.
Our study had several limitations. First, despite the large sample size, our study had limited power to detect HLAassociated viral polymorphisms for rare HLA alleles. Second, although we checked for phylogenetic relatedness, we cannot exclude the possibility that in some instances an association between an HLA allele and viral polymorphism may be secondary to founder effects (3). Third, we identified putative epitopes and escape mutations only by using epitope prediction programs. Functional analysis to determine the presence of epitope-specific CD8 T cells in HLA-matched individuals with chronic or acute HBV infections will be needed to confirm the immunogenicity of these predicted epitopes. Changes in HLA binding in the presence and absence of the identified polymorphism should also be examined by functional testing. These experiments are under way. Fourth, to demonstrate true viral adaptation or immune evasion at the time of HBeAg se-roconversion, it would be best to assess this in a longitudinal cohort, which was not possible with our current cohort. Finally, in this study, we assessed HBV DNA only from plasma, although it is possible that quasispecies variation or adaptation may be different in HBV DNA from infected hepatocytes, where antigen presentation likely occurs. Analysis and comparison of plasma-and liver-derived HBV sequences would be important in future studies.
We have carried out a comprehensive analysis of viral polymorphisms and their associations with the HLA type across the full HBV proteome, with adjustment for potential phylogenetic relatedness between viral sequences and linkage disequilibrium between coinherited HLA alleles. We showed differences in patterns of viral adaptation to HLA-restricted immune pressure between HBV genotypes B and C. Greater viral adaptation was observed in HBeAg-negative individuals, consistent with the concept that the transition from HBeAg-positive to HBeAg-negative disease is associated with significant immune pressure on the virus. Despite the low frequency of circulating HBV-specific T cells, there is evidence that HBV is under substantial immune pressure. Understanding key epitopes associated with immune pressure may potentially lead to new therapeutic strategies for the management of chronic HBV infection.
